Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Titel:
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Auteur:
Oliveira, Mafalda Pominchuk, Denys Nowecki, Zbigniew Hamilton, Erika Kulyaba, Yaroslav Andabekov, Timur Hotko, Yevhen Melkadze, Tamar Nemsadze, Gia Neven, Patrick Vladimirov, Vladimir Zamagni, Claudio Denys, Hannelore Forget, Frédéric Horvath, Zsolt Nesterova, Alfiya Ajimi, Maxine Kirova, Bistra Klinowska, Teresa Lindemann, Justin P O Lissa, Delphine Mathewson, Alastair Morrow, Christopher J Traugottova, Zuzana van Zyl, Ruaan Arkania, Ekaterine